Myung In Pharmaceutical LTD. (KRX:317450)
South Korea · Delayed Price · Currency is KRW 104,200
-5,500 (-5.01%)
At close: Oct 15, 2025
KRX:317450 Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Net Income | 77,916 | 68,671 | 74,512 | 57,434 | 59,750 | 45,478 | Upgrade |
Depreciation & Amortization | 12,592 | 12,463 | 11,440 | 11,336 | 11,619 | 10,961 | Upgrade |
Loss (Gain) From Sale of Assets | 703.18 | 609.54 | 0.32 | -10.7 | -6.39 | 99.44 | Upgrade |
Loss (Gain) From Sale of Investments | 8,310 | 8,310 | -826.42 | - | - | 3,484 | Upgrade |
Provision & Write-off of Bad Debts | 306.4 | -306.25 | 60.61 | -207.87 | 165.58 | -1,263 | Upgrade |
Other Operating Activities | -1,174 | -1,522 | 3,787 | 924.41 | 2,025 | 5,454 | Upgrade |
Change in Accounts Receivable | -483.9 | 941.39 | 262.81 | 2,166 | 579.21 | -744.81 | Upgrade |
Change in Inventory | -1,391 | -5,205 | -8,679 | -1,264 | -2,511 | -13,769 | Upgrade |
Change in Accounts Payable | 4,407 | 5,789 | 268.26 | -115.86 | 236.65 | -922.52 | Upgrade |
Change in Other Net Operating Assets | -8,423 | -6,777 | -4,750 | -9,217 | -5,754 | 6,294 | Upgrade |
Operating Cash Flow | 92,761 | 82,972 | 76,075 | 61,045 | 66,105 | 55,071 | Upgrade |
Operating Cash Flow Growth | 51.95% | 9.07% | 24.62% | -7.65% | 20.04% | 28.31% | Upgrade |
Capital Expenditures | -17,689 | -10,189 | -4,647 | -3,402 | -2,697 | -9,583 | Upgrade |
Sale of Property, Plant & Equipment | 11.5 | 180.61 | - | 13.5 | 6 | 19 | Upgrade |
Sale (Purchase) of Intangibles | -3,368 | -3.26 | -1.43 | -0.56 | 319.08 | -2.35 | Upgrade |
Investment in Securities | -108,639 | -74,925 | -28,866 | -68,030 | -65,086 | -20,085 | Upgrade |
Other Investing Activities | 8,472 | 8,041 | -6,295 | -17,527 | -5,915 | 6,121 | Upgrade |
Investing Cash Flow | -121,213 | -76,895 | -39,810 | -88,946 | -73,374 | -23,529 | Upgrade |
Long-Term Debt Issued | - | - | 3,840 | 5,480 | 1,052 | 1,000 | Upgrade |
Total Debt Issued | - | - | 3,840 | 5,480 | 1,052 | 1,000 | Upgrade |
Long-Term Debt Repaid | - | -2,075 | -1,459 | -1,492 | -1,422 | -528.86 | Upgrade |
Total Debt Repaid | -2,067 | -2,075 | -1,459 | -1,492 | -1,422 | -528.86 | Upgrade |
Net Debt Issued (Repaid) | -2,067 | -2,075 | 2,381 | 3,989 | -369.77 | 471.14 | Upgrade |
Dividends Paid | -11,200 | -5,600 | -22,400 | -11,200 | -14,000 | -19,600 | Upgrade |
Financing Cash Flow | -13,267 | -7,675 | -20,019 | -7,211 | -14,370 | -19,129 | Upgrade |
Foreign Exchange Rate Adjustments | 2,015 | 45.27 | -48.1 | 396.58 | 4,102 | -2,991 | Upgrade |
Net Cash Flow | -39,704 | -1,552 | 16,198 | -34,716 | -17,537 | 9,422 | Upgrade |
Free Cash Flow | 75,072 | 72,783 | 71,428 | 57,643 | 63,407 | 45,488 | Upgrade |
Free Cash Flow Growth | 30.24% | 1.90% | 23.91% | -9.09% | 39.39% | 23.79% | Upgrade |
Free Cash Flow Margin | 26.75% | 27.01% | 29.47% | 25.52% | 30.30% | 24.22% | Upgrade |
Free Cash Flow Per Share | 6702.89 | 6498.51 | 6377.48 | 5146.68 | 5661.37 | 4061.46 | Upgrade |
Cash Interest Paid | - | - | - | - | 137.2 | - | Upgrade |
Cash Income Tax Paid | 22,054 | 22,782 | 16,300 | 26,812 | 15,695 | 14,345 | Upgrade |
Levered Free Cash Flow | - | 60,205 | 51,018 | 48,309 | 56,598 | 34,872 | Upgrade |
Unlevered Free Cash Flow | - | 60,406 | 51,227 | 48,376 | 56,681 | 34,902 | Upgrade |
Change in Working Capital | -5,891 | -5,252 | -12,898 | -8,430 | -7,449 | -9,143 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.